{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:35:26Z","timestamp":1794951326784,"version":"4.9.1"},"reference-count":158,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.eururo.2024.04.010","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T08:20:04Z","timestamp":1714378804000},"page":"164-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":401,"title":["EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II\u20142024 Update: Treatment of Relapsing and Metastatic Prostate Cancer"],"prefix":"10.1016","volume":"86","author":[{"given":"Derya","family":"Tilki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick C.N.","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Briers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Van den Broeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Brunckhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Darraugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Eberli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"De Meerleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Farolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lardas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"J.L.H. van Leenders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefania","family":"Linares Espinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rouvi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo G.","family":"Schoots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1918-2073","authenticated-orcid":false,"given":"Natasha","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Stranne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter-Paul M.","family":"Willemse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Cornford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2024.04.010_b0005","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II\u20142020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0010","doi-asserted-by":"crossref","unstructured":"Cornford et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024 Apr 12:S0302-2838(24)02254-1. doi: 10.1016\/j.eururo.2024.03.027. Online ahead of print. PMID: 38614820.","DOI":"10.1016\/j.eururo.2024.03.027"},{"key":"10.1016\/j.eururo.2024.04.010_b0015","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":"Going from evidence to recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2024.04.010_b0020","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0022-5347(05)66452-X","article-title":"Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?","volume":"165","author":"Amling","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0025","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.juro.2015.12.075","article-title":"Standardizing the definition of biochemical recurrence after radical prostatectomy\u2014what prostate specific antigen cut point best predicts a durable increase and subsequent systemic progression?","volume":"195","author":"Toussi","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0030","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1200\/JCO.2005.04.0756","article-title":"Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition","volume":"24","author":"Stephenson","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0035","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2024.04.010_b0040","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review","volume":"75","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0045","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.eururo.2019.03.016","article-title":"External validation of the European Association of Urology biochemical recurrence risk groups to predict metastasis and mortality after radical prostatectomy in a European cohort","volume":"75","author":"Tilki","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0050","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","article-title":"Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET\/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy","volume":"56","author":"Morigi","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","article-title":"Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer","volume":"41","author":"Afshar-Oromieh","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2024.04.010_b0060","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00259-018-4067-3","article-title":"68Ga-PSMA PET\/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients","volume":"45","author":"Caroli","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2024.04.010_b0065","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1007\/s00330-009-1647-4","article-title":"Imaging of prostate cancer local recurrences: why and how?","volume":"20","author":"Rouviere","year":"2010","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2024.04.010_b0070","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/jmri.26581","article-title":"Quantitative 3T multiparametric MRI of benign and malignant prostatic tissue in patients with and without local recurrent prostate cancer after external-beam radiation therapy","volume":"50","author":"Dinis Fernandes","year":"2019","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.eururo.2024.04.010_b0075","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1148\/radiol.13122149","article-title":"Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy?","volume":"268","author":"Donati","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2024.04.010_b0080","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.04.010_b0085","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0090","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0095","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3390\/cancers14030740","article-title":"Salvage radiotherapy versus observation for biochemical recurrence following radical prostatectomy for prostate cancer: a matched pair analysis","volume":"14","author":"Tilki","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2024.04.010_b0100","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1016\/j.juro.2009.08.027","article-title":"Radiation therapy after radical prostatectomy: impact on metastasis and survival","volume":"182","author":"Boorjian","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0105","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.22.02489","article-title":"Prostate-specific antigen level at the time of salvage therapy after radical prostatectomy for prostate cancer and the risk of death","volume":"41","author":"Tilki","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0110","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2023.05.038","article-title":"European Association of Urology biochemical recurrence risk classification as a decision tool for salvage radiotherapy\u2014a multicenter study","volume":"85","author":"Preisser","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0115","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","article-title":"Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial","volume":"20","author":"Carrie","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0120","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0125","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.04.010_b0130","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.eururo.2017.06.027","article-title":"A systematic review and framework for the use of hormone therapy with salvage radiation therapy for recurrent prostate cancer","volume":"73","author":"Spratt","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0135","doi-asserted-by":"crossref","first-page":"866","DOI":"10.2967\/jnumed.119.235028","article-title":"3-Year freedom from progression after 68Ga-PSMA PET\/CT-triaged management in men with biochemical recurrence after radical prostatectomy: results of a prospective multicenter trial","volume":"61","author":"Emmett","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0140","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.04.010_b0145","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/cncr.29983","article-title":"Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: a randomized clinical trial","volume":"122","author":"Viani","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2024.04.010_b0150","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1200\/JCO.20.03714","article-title":"Adjuvant versus early salvage radiation therapy for men at high risk for recurrence following radical prostatectomy for prostate cancer and the risk of death","volume":"39","author":"Tilki","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0155","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER)","volume":"80","author":"Valle","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0160","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0165","doi-asserted-by":"crossref","unstructured":"Freedland SJ, Gleave M, De Giorgi U, et al. Enzalutamide and quality of life in biochemically recurrent prostate cancer. NEJM Evid 2023;2:EVIDoa2300251.","DOI":"10.1056\/EVIDoa2300251"},{"key":"10.1016\/j.eururo.2024.04.010_b0170","unstructured":"US Food and Drug Administration. FDA approves enzalutamide for non-metastatic castration-sensitive prostate cancer with biochemical recurrence. FDA; 2023. http:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-enzalutamide-non-metastatic-castration-sensitive-prostate-cancer-biochemical-recurrence."},{"key":"10.1016\/j.eururo.2024.04.010_b0175","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2018.10.041","article-title":"Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review","volume":"76","author":"Ploussard","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0180","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.eururo.2020.06.043","article-title":"Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought","volume":"78","author":"Bravi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0185","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2022.05.031","article-title":"Cohort study of oligorecurrent prostate cancer patients: oncological outcomes of patients treated with salvage lymph node dissection via prostate-specific membrane antigen-radioguided surgery","volume":"83","author":"Knipper","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0190","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2021.06.010","article-title":"OLIGOPELVIS GETUG P07, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate cancer","volume":"80","author":"Supiot","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0195","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.eururo.2019.07.009","article-title":"Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy","volume":"76","author":"De Bleser","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0200","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s11912-022-01323-y","article-title":"A systematic review and a meta-analysis of randomized controlled trials' control groups in metastatic hormone-sensitive prostate cancer (mHSPC)","volume":"24","author":"Napoli","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.eururo.2024.04.010_b0205","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0210","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0215","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.eururo.2018.02.001","article-title":"Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies","volume":"73","author":"Gravis","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0220","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.04.010_b0225","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","author":"Francini","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2024.04.010_b0230","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","article-title":"Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)","volume":"24","author":"Hussain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0235","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2017.75.3921","article-title":"Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel","volume":"36","author":"Harshman","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0240","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.eururo.2019.11.021","volume":"77","author":"Matsubara","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0245","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer","volume":"34","author":"Chowdhury","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0250","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eururo.2011.08.026","article-title":"Contemporary role of androgen deprivation therapy for prostate cancer","volume":"61","author":"Pagliarulo","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0255","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0260","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00345-020-03433-3","article-title":"Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice","volume":"39","author":"Davey","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0265","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11886-021-01561-9","article-title":"Cardiovascular toxicity of androgen deprivation therapy","volume":"23","author":"Boland","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.eururo.2024.04.010_b0270","doi-asserted-by":"crossref","first-page":"1157857","DOI":"10.3389\/fendo.2023.1157857","article-title":"Adverse cardiovascular effect following gonadotropin-releasing hormone antagonist versus GnRH agonist for prostate cancer treatment: a systematic review and meta-analysis","volume":"14","author":"Gu","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.eururo.2024.04.010_b0275","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0280","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0285","first-page":"CD012816","article-title":"Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer","volume":"2018","author":"Sathianathen","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2024.04.010_b0290","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","article-title":"Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials","volume":"24","author":"Vale","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0295","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0300","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0305","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2017.07.003","article-title":"Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"84","author":"Rydzewska","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2024.04.010_b0310","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","article-title":"Abiraterone in \u201chigh-\u201d and \u201clow-risk\u201d metastatic hormone-sensitive prostate cancer","volume":"76","author":"Hoyle","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0315","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0320","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0325","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0330","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0335","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S1470-2045(22)00507-1","article-title":"Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial","volume":"23","author":"Gu","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0340","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.04.010_b0345","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0350","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0355","doi-asserted-by":"crossref","first-page":"e1003998","DOI":"10.1371\/journal.pmed.1003998","article-title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial","volume":"19","author":"Parker","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0360","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamaoncol.2020.7857","article-title":"Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial","volume":"7","author":"Ali","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0365","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0370","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0375","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0380","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0385","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2021.02.031","article-title":"Curative-intent metastasis-directed therapies for molecularly-defined oligorecurrent prostate cancer: a prospective phase II trial testing the oligometastasis hypothesis","volume":"80","author":"Glicksman","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0390","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.euo.2018.09.005","article-title":"Novel insights into the management of oligometastatic prostate cancer: a comprehensive review","volume":"2","author":"Battaglia","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0395","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.euo.2020.07.004","article-title":"Targeting oligometastasis with stereotactic ablative radiation therapy or surgery in metastatic hormone-sensitive prostate cancer: a systematic review of prospective clinical trials","volume":"3","author":"Connor","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0400","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0405","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0410","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0415","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide","volume":"383","author":"Fizazi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0420","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","article-title":"Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer","volume":"382","author":"Sternberg","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0425","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","article-title":"Apalutamide and overall survival in prostate cancer","volume":"79","author":"Smith","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0430","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0435","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ejca.2015.06.128","article-title":"Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer","volume":"51","author":"Loriot","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2024.04.010_b0440","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0445","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0450","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1470-2045(15)00518-5","article-title":"Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study","volume":"17","author":"Shore","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0455","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.eururo.2016.06.033","article-title":"Subsequent chemotherapy and treatment patterns after abiraterone acetate in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302","volume":"71","author":"de Bono","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0460","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0465","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0470","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0475","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-18-0981","article-title":"Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss","volume":"25","author":"de Bono","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2024.04.010_b0480","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.04.010_b0485","doi-asserted-by":"crossref","unstructured":"Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid 2022;1:EVIDoa2200043.","DOI":"10.1056\/EVIDoa2200043"},{"key":"10.1016\/j.eururo.2024.04.010_b0490","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0495","unstructured":"European Medicines Agency. Lynparza (olaparib). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lynparza."},{"key":"10.1016\/j.eururo.2024.04.010_b0500","unstructured":"US Food and Drug Administration. D.I.S.C.O. burst edition: FDA approval of Lynparza (olaparib), with abiraterone and prednisone, for BRCA-mutated metastatic castration-resistant prostate cancer. 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approval-lynparza-olaparib-abiraterone-and-prednisone-brca-mutated."},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.04.010_b0505","first-page":"2","volume":"40","author":"Chi","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0510","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0515","unstructured":"European Medicines Agency. Akeega. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/akeega."},{"key":"10.1016\/j.eururo.2024.04.010_b0520","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.04.010_b0525","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"Fizazi","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0530","unstructured":"US Food and Drug Administration. FDA approves talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer. FDA, June 20, 2023. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate."},{"key":"10.1016\/j.eururo.2024.04.010_b0535","unstructured":"European Medicines Agency. Talzenna - opinion on variation to marketing authorisation. EMA November 23, 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/variation\/talzenna."},{"key":"10.1016\/j.eururo.2024.04.010_b0540","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0545","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0550","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.eururo.2014.02.056","article-title":"Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)","volume":"66","author":"Rathkopf","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0555","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0560","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0565","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.04.010_b0570","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0575","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0580","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0585","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0590","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0595","unstructured":"European Medicines Agency. EMA restricts use of prostate cancer medicine Xofigo. EMA, July 27, 2018. https:\/\/www.ema.europa.eu\/en\/news\/ema-restricts-use-prostate-cancer-medicine-xofigo."},{"key":"10.1016\/j.eururo.2024.04.010_b0600","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0605","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.04.010_b0610","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1200\/JCO.2023.41.6_suppl.18","article-title":"Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy","volume":"41","author":"Bryce","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0615","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0620","doi-asserted-by":"crossref","first-page":"S507","DOI":"10.1016\/j.annonc.2020.08.870","article-title":"610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician\u2019s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations","volume":"31","author":"de Bono","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0625","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/cncr.28518","article-title":"Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment","volume":"120","author":"Badrising","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2024.04.010_b0630","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1517\/14656566.2015.995090","article-title":"Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer","volume":"16","author":"Zhang","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.eururo.2024.04.010_b0635","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0640","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.2018.77.9827","article-title":"Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment","volume":"36","author":"Attard","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0645","doi-asserted-by":"crossref","first-page":"20170969","DOI":"10.1259\/bjr.20170969","article-title":"Theranostic radiopharmaceuticals: established agents in current use","volume":"91","author":"Ballinger","year":"2018","journal-title":"Br J Radiol"},{"key":"10.1016\/j.eururo.2024.04.010_b0650","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/jmrs.227","article-title":"Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy","volume":"64","author":"Emmett","year":"2017","journal-title":"J Med Radiat Sci"},{"key":"10.1016\/j.eururo.2024.04.010_b0655","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"issue":"16 Suppl","key":"10.1016\/j.eururo.2024.04.010_b0660","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1200\/JCO.2022.40.16_suppl.5000","article-title":"TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel\u2014overall survival after median follow-up of 3 years (ANZUP 1603)","volume":"40","author":"Hofman","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0665","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0670","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/pros.24325","article-title":"177Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: an updated systematic review and meta-analysis","volume":"82","author":"Sadaghiani","year":"2022","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2024.04.010_b0675","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0680","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.04.010_b0685","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/annonc\/mdw156","article-title":"Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review","volume":"27","author":"Hager","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0690","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S1470-2045(19)30408-5","article-title":"Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1\u20132 trial","volume":"20","author":"Corn","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0695","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2024.04.010_b0700","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1200\/PO.19.00346","article-title":"Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations","volume":"4","author":"Mota","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0705","doi-asserted-by":"crossref","first-page":"e2021692","DOI":"10.1001\/jamanetworkopen.2020.21692","article-title":"Activity of platinum-based chemotherapy in patients with advanced prostate cancer with and without DNA repair gene aberrations","volume":"3","author":"Schmid","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eururo.2024.04.010_b0710","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1093\/annonc\/mdt194","article-title":"Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial","volume":"24","author":"Bahl","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0715","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/annonc\/mdv257","article-title":"Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015","volume":"26","author":"Gillessen","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0720","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.eururo.2020.08.025","article-title":"Prostate-specific antigen progression in enzalutamide-treated men with nonmetastatic castration-resistant prostate cancer: any rise in prostate-specific antigen may require closer monitoring","volume":"78","author":"Saad","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0725","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.euo.2018.03.010","article-title":"Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer","volume":"1","author":"Aggarwal","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0730","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.urolonc.2009.11.003","article-title":"Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer","volume":"29","author":"Payne","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0735","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.eururo.2013.10.055","article-title":"Visceral disease in castration-resistant prostate cancer","volume":"65","author":"Pezaro","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.04.010_b0740","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0745","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2024.04.010_b0750","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.04.010_b0755","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.04.010_b0760","doi-asserted-by":"crossref","first-page":"642","DOI":"10.2106\/00004623-200005000-00005","article-title":"Functional and oncological outcome of acetabular reconstruction for the treatment of metastatic disease","volume":"82","author":"Marco","year":"2000","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.eururo.2024.04.010_b0765","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00520-015-2904-5","article-title":"Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer","volume":"24","author":"Stopeck","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.eururo.2024.04.010_b0770","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0775","doi-asserted-by":"crossref","unstructured":"Otto S, editor. Medication-related osteonecrosis of the jaws: bisphosphonates, denosumab, and new agents. Berlin\/Heidelberg: Springer; 2015.","DOI":"10.1007\/978-3-662-43733-9"},{"key":"10.1016\/j.eururo.2024.04.010_b0780","unstructured":"European Medicines Agency: Xgeva. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xgeva."},{"key":"10.1016\/j.eururo.2024.04.010_b0785","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.04.010_b0790","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.ejca.2015.05.016","article-title":"Hypocalcaemia in patients with metastatic bone disease treated with denosumab","volume":"51","author":"Body","year":"2015","journal-title":"Eur J Cancer"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824023066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824023066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T13:23:10Z","timestamp":1722518590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283824023066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":158,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0302283824023066"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2024.04.010","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II\u20142024 Update: Treatment of Relapsing and Metastatic Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2024.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}